Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS) : A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients. / Jensen, Oda; Øvlisen, Andreas Kiesbye; Jakobsen, Lasse Hjort; Roug, Anne Stidsholt; Nielsen, René Ernst; Marcher, Claus Werenberg; Ebbesen, Lene Hyldahl; Theilgaard-Mönch, Kim; Møller, Peter; Schöllkopf, Claudia; Torp-Pedersen, Christian; El-Galaly, Tarec Christoffer; Severinsen, Marianne Tang.

I: Clinical Epidemiology, Bind 14, 2022, s. 225-237.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Jensen, O, Øvlisen, AK, Jakobsen, LH, Roug, AS, Nielsen, RE, Marcher, CW, Ebbesen, LH, Theilgaard-Mönch, K, Møller, P, Schöllkopf, C, Torp-Pedersen, C, El-Galaly, TC & Severinsen, MT 2022, 'Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients', Clinical Epidemiology, bind 14, s. 225-237. https://doi.org/10.2147/CLEP.S336115

APA

Jensen, O., Øvlisen, A. K., Jakobsen, L. H., Roug, A. S., Nielsen, R. E., Marcher, C. W., Ebbesen, L. H., Theilgaard-Mönch, K., Møller, P., Schöllkopf, C., Torp-Pedersen, C., El-Galaly, T. C., & Severinsen, M. T. (2022). Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients. Clinical Epidemiology, 14, 225-237. https://doi.org/10.2147/CLEP.S336115

Vancouver

Jensen O, Øvlisen AK, Jakobsen LH, Roug AS, Nielsen RE, Marcher CW o.a. Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients. Clinical Epidemiology. 2022;14:225-237. https://doi.org/10.2147/CLEP.S336115

Author

Jensen, Oda ; Øvlisen, Andreas Kiesbye ; Jakobsen, Lasse Hjort ; Roug, Anne Stidsholt ; Nielsen, René Ernst ; Marcher, Claus Werenberg ; Ebbesen, Lene Hyldahl ; Theilgaard-Mönch, Kim ; Møller, Peter ; Schöllkopf, Claudia ; Torp-Pedersen, Christian ; El-Galaly, Tarec Christoffer ; Severinsen, Marianne Tang. / Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS) : A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients. I: Clinical Epidemiology. 2022 ; Bind 14. s. 225-237.

Bibtex

@article{2b34247281e344dfa807e7a63b8cf7cb,
title = "Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients",
abstract = "Introduction: The diagnosis of a life-threatening disease can lead to depression and anxiety resulting in pharmacological treatment. However, use of psychotropic drugs (antidepressants, anxiolytics, and antipsychotics) in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) is undetermined.Methods: Prescription of psychotropic drugs in Danish AML and MDS patients was compared to a cohort matched on age, sex, and country of origin from the Danish background population using national population-based registries.Results: In total, 2404 AML patients (median age 69 years) and 1307 MDS patients (median age 75 years) were included and each matched to five comparators from the background population. Two-year cumulative incidences showed that AML (20.6%) and MDS (21.2%) patients had a high risk of redemption of a psychotropic drug prescription compared to the background population (7.0% and 7.9%). High age, low educational level, and Charlson Comorbidity Index score ≥1 was associated with a higher risk in AML and MDS patients. Furthermore, non-curative treatment intent and performance status in AML patients, and high risk MDS were associated with elevated risk of psychotropic drug prescription.Conclusion: In conclusion, diagnoses of AML and MDS were associated with a higher rate of psychotropic drugs prescription compared to the background population.",
author = "Oda Jensen and {\O}vlisen, {Andreas Kiesbye} and Jakobsen, {Lasse Hjort} and Roug, {Anne Stidsholt} and Nielsen, {Ren{\'e} Ernst} and Marcher, {Claus Werenberg} and Ebbesen, {Lene Hyldahl} and Kim Theilgaard-M{\"o}nch and Peter M{\o}ller and Claudia Sch{\"o}llkopf and Christian Torp-Pedersen and El-Galaly, {Tarec Christoffer} and Severinsen, {Marianne Tang}",
note = "{\textcopyright} 2022 Jensen et al.",
year = "2022",
doi = "10.2147/CLEP.S336115",
language = "English",
volume = "14",
pages = "225--237",
journal = "Clinical Epidemiology",
issn = "1179-1349",
publisher = "Dove Medical Press Ltd",

}

RIS

TY - JOUR

T1 - Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS)

T2 - A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients

AU - Jensen, Oda

AU - Øvlisen, Andreas Kiesbye

AU - Jakobsen, Lasse Hjort

AU - Roug, Anne Stidsholt

AU - Nielsen, René Ernst

AU - Marcher, Claus Werenberg

AU - Ebbesen, Lene Hyldahl

AU - Theilgaard-Mönch, Kim

AU - Møller, Peter

AU - Schöllkopf, Claudia

AU - Torp-Pedersen, Christian

AU - El-Galaly, Tarec Christoffer

AU - Severinsen, Marianne Tang

N1 - © 2022 Jensen et al.

PY - 2022

Y1 - 2022

N2 - Introduction: The diagnosis of a life-threatening disease can lead to depression and anxiety resulting in pharmacological treatment. However, use of psychotropic drugs (antidepressants, anxiolytics, and antipsychotics) in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) is undetermined.Methods: Prescription of psychotropic drugs in Danish AML and MDS patients was compared to a cohort matched on age, sex, and country of origin from the Danish background population using national population-based registries.Results: In total, 2404 AML patients (median age 69 years) and 1307 MDS patients (median age 75 years) were included and each matched to five comparators from the background population. Two-year cumulative incidences showed that AML (20.6%) and MDS (21.2%) patients had a high risk of redemption of a psychotropic drug prescription compared to the background population (7.0% and 7.9%). High age, low educational level, and Charlson Comorbidity Index score ≥1 was associated with a higher risk in AML and MDS patients. Furthermore, non-curative treatment intent and performance status in AML patients, and high risk MDS were associated with elevated risk of psychotropic drug prescription.Conclusion: In conclusion, diagnoses of AML and MDS were associated with a higher rate of psychotropic drugs prescription compared to the background population.

AB - Introduction: The diagnosis of a life-threatening disease can lead to depression and anxiety resulting in pharmacological treatment. However, use of psychotropic drugs (antidepressants, anxiolytics, and antipsychotics) in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) is undetermined.Methods: Prescription of psychotropic drugs in Danish AML and MDS patients was compared to a cohort matched on age, sex, and country of origin from the Danish background population using national population-based registries.Results: In total, 2404 AML patients (median age 69 years) and 1307 MDS patients (median age 75 years) were included and each matched to five comparators from the background population. Two-year cumulative incidences showed that AML (20.6%) and MDS (21.2%) patients had a high risk of redemption of a psychotropic drug prescription compared to the background population (7.0% and 7.9%). High age, low educational level, and Charlson Comorbidity Index score ≥1 was associated with a higher risk in AML and MDS patients. Furthermore, non-curative treatment intent and performance status in AML patients, and high risk MDS were associated with elevated risk of psychotropic drug prescription.Conclusion: In conclusion, diagnoses of AML and MDS were associated with a higher rate of psychotropic drugs prescription compared to the background population.

U2 - 10.2147/CLEP.S336115

DO - 10.2147/CLEP.S336115

M3 - Journal article

C2 - 35241936

VL - 14

SP - 225

EP - 237

JO - Clinical Epidemiology

JF - Clinical Epidemiology

SN - 1179-1349

ER -

ID: 303373877